Get the Stockscreener App
6.35
4.61%
0.28
Exicure Inc stock is traded at $6.35, with a volume of 218.70K.
It is up +4.61% in the last 24 hours and up +76.39% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$6.07
Open:
$5.85
24h Volume:
218.70K
Relative Volume:
0.37
Market Cap:
$40.47M
Revenue:
$500.00K
Net Income/Loss:
$-7.88M
P/E Ratio:
-3.7485
EPS:
-1.694
Net Cash Flow:
$-5.49M
1W Performance:
+29.59%
1M Performance:
+76.39%
6M Performance:
-29.37%
1Y Performance:
-63.71%
1-Day Range:
$5.6001
$6.55
1-Week Range:
$4.87
$9.4799
52-Week Range:
$3.1006
$22.99
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.66 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.30 | 268.44M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
5.14 | 223.06M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.7287 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.74 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Exicure stock soars 40% after stem cell drug helps most patients hit phase 2 goal — traders call it 'cheap' at current levels - MSN
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know - ts2.tech
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
Sangsangin investment sells Exicure (XCUR) shares worth $3.77 million By Investing.com - Investing.com Nigeria
Morning Market Movers: ASPC, ENVB, AFJK, JXG See Big Swings - RTTNews
Exicure’s Stunning Rise: What’s Fueling It? - StocksToTrade
Exicure Shares Surge 41% On Promising Phase 2 Data For Multiple Myeloma Drug - Nasdaq
Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels - Asianet Newsable
Exicure’s Risky Bet On Stem Cell Mobilization Pays Early Dividends - Finimize
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial - Benzinga
Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - ts2.tech
Exicure (XCUR) Stock: Biotech Soars on Promising Cancer Drug Data - parameter.io
ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma - Fierce Biotech
Dow Surges Over 100 Points; Campbell's Posts Upbeat Earnings - Benzinga
This BlackRock stock just rocketed 70% - Finbold
Exicure (XCUR) Stock: Biotech Shares Surge 140% on Cancer Drug Breakthrough - Blockonomi
Exicure Inc.: Is It a Bet Worth Taking? - timothysykes.com
Exicure Inc (XCUR) expanding its growth trajectory ahead - setenews.com
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
Morning Market Movers: ATMC, XCUR, VOR, ATMV See Big Swings - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Exicure Soars On Burixafor Data In Multiple Myeloma Trial - Nasdaq
Exicure Inc. (XCUR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance - Nasdaq
Exicure reports positive Phase 2 results for multiple myeloma therapy By Investing.com - Investing.com Nigeria
Exicure (XCUR) Sees Positive Phase 2 Trial Results for Burixafor in Multiple Myeloma - GuruFocus
Exicure presents topline data from burixafor combination trial - TipRanks
Exicure stock soars after positive Phase 2 data for multiple myeloma drug - Investing.com
Exicure, Inc. Reports Positive Phase 2 Trial Results for Burixafor in Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma Patients - Quiver Quantitative
Exicure, Inc. Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma At 2025 Ash Annual Meeting - marketscreener.com
KOSDAQ firm The Technology buys Exicure Hitechron amid embezzlement probe, sparking insider trading suspicionsCHOSUNBIZ - Chosunbiz
Exicure Inc Trading Resumes - MSN
What analysts say about Exicure Inc stockPrice Action Analysis & Use Time as Your Investing Ally - earlytimes.in
Exicure Inc 2H0 Stock Analysis and ForecastMarket Sentiment Shifts & Free Exceptional Market Positioning - earlytimes.in
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Exicure Stock Surges 76%, With A 6-Day Winning Spree - Trefis
(XCUR) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
How Exicure Inc. (2H0) stock expands through international marketsGlobal Markets & Weekly Stock Breakout Alerts - Newser
How Exicure Inc. (2H0) stock correlates with oil marketsBond Market & AI Powered Market Trend Analysis - Newser
Will Exicure Inc. stock gain from strong economy2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
How Exicure Inc. (2H0) stock compares with tech leadersJuly 2025 Earnings & Long Hold Capital Preservation Tips - Newser
How Exicure Inc. (2H0) stock compares with market leadersQuarterly Profit Report & Growth Focused Entry Reports - Newser
Should I buy Exicure Inc. (2H0) stock before earnings seasonJuly 2025 EndofMonth & Weekly Top Gainers Alerts - Newser
Can Exicure Inc. (2H0) stock test all time highsSell Signal & Safe Entry Trade Reports - Newser
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Total assets of Exicure, Inc. – SWB:2H0 - TradingView
Exicure Redeems Convertible Bonds for Liquidity - MSN
Will Kanishk Steel Industries Limited Stock Continue to Outperform in YEARInsider Buying Signals & Free Tremendous Portfolio Expansion - earlytimes.in
What drives Exicure Inc stock priceInsider Buying Signals & Fast Profit Portfolio Plans - earlytimes.in
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Should I hold or sell Exicure Inc. stock in 2025Gap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):